Overview
Chlorquinaldol was used historically as a topical antiseptic under the trade name Sterosan. It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.
Indication
Chlorquinaldol was used historically as a topical antiseptic agent for skin infections. It maintains use in European countries as a combination vaginal tablet with promestriene for use in the treatment of vaginal infections.
Associated Conditions
- Allergic Skin Reaction
- Dermatitis
- Fungal skin infection
- Skin Infections
- Vaginal atrophy with infection
Research Report
Chlorquinaldol Report
Name: Chlorquinaldol Name (English): Chlorquinaldol DrugBank ID: DB13306 Type: Small Molecule CAS Number: 72-80-0
Synonyms: 2-methyl-5,7-dichloro-8-hydroxyquinoline, 5,7-dichloro-2-methyl-8-hydroxyquinoline, 5,7-dichloro-2-methyl-8-quinolinol, 5,7-dichloro-8-hydroxy-2-methylquinoline, 5,7-dichloro-8-hydroxyquinaldine, 5,7-dichloro-8-quinaldinol, Chlorchinaldol, Chlorquinaldolum, Chloquinan, Chlorchinaldin, Chlorguinaldon, Chloroquinaldol, Florabina, Gyno-Sterosan, Hydroxydichloroquinaldine, Intensol, Saprosan, Siogen, Siogenal, Siogene, Siogeno, Siogenon, Siosept, Siosteran, Sterosan, Steroxin, Sterozan, Vagisteran, 5,7-dichloro-2-methylquinolin-8-ol.
Pharmacology:
- Indication: Historically used as a topical antiseptic agent for skin infections. Currently used in European countries as a combination vaginal tablet with promestriene for the treatment of vaginal infections. Also used for skin, gastrointestinal, and vaginal infections with fungi, protozoa, and certain bacteria. Used in combination to treat vaginal atrophy with infection and for symptomatic treatment of allergic skin manifestations, and prophylaxis and treatment of mycotic skin infection (in combination with difluocortolone).
- Mechanism of Action: Bactericidal against both gram-positive and gram-negative bacteria, more effective against gram-positive bacteria, particularly staphylococci. The exact mechanism of its bactericidal effect is unknown, but 8-hydroxyquinolines are known to be bidentate chelators of several metal ions which act as critical enzyme cofactors. Does not appear to rely on chelation as the primary mechanism. Disrupts the cell membranes of bacteria and fungi and may interfere with their DNA replication processes. Exhibits anti-inflammatory properties.
- Pharmacodynamics: Bactericidal effect against various microorganisms.
- Absorption: Variable absorption (4.2 to 23.5%) after topical application. Oral absorption i
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2010/06/30 | Phase 4 | Terminated |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.